ESTRO 2025 - Abstract Book

S1610

Clinical – Mixed sites & palliation

ESTRO 2025

Conclusion: Preclinically, PAT plans have consistently demonstrated superior plan quality in comparison to MFO plans. For the first time worldwide, patients have been treated with this new delivery technique clinically, using discretized arcs with the same advantages observed for PAT in the in-silico trials. The Proton Arc Therapy paradigm has therefore been successfully introduced into the clinical routine, facilitating planning for complex treatment situations and potentially further reducing toxicity

Keywords: proton therapy, head and neck, toxicity

4579

Digital Poster Radiotherapy for Managing Sialorrhea in Amyotrophic Lateral Sclerosis: A Palliative Approach for Patients with Poor Clinical Condition Miroslava Slavikova 1 , Ludmila Hynkova 1,2 , Marek Slavik 1,2 , Pavel Slampa 1,2 1 Department of Radiation Oncology, Masaryk Memorial Institute, Brno, Czech Republic. 2 Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic Purpose/Objective: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by motor neuron loss, leading to significant symptoms such as dysphagia and sialorrhea. This report evaluates the use of radiotherapy (RT) targeting salivary glands as a non-invasive treatment for hypersalivation in ALS patients, focusing on treatment outcomes and tolerability. Material/Methods: Six ALS patients with severe sialorrhea refractory to anticholinergics and botulinum toxin were treated between March 2020 and July 2024. All patients presented with bulbar symptoms, including dysarthria and dysphagia. Bilateral parotid and submandibular glands were irradiated using 150 kV orthovoltage X-rays with a simple direct field technique (Fig.1). Orthovoltage X-rays were chosen due to the poor clinical condition of the patients, who were unable to lie in a supine position. The total doses were 5 Gy in one fraction (1 patient) and 10 Gy in two fractions for the remaining five patients, with intervals of 1 week to 3 months, depending on the severity of symptoms, therapeutic effect, and toxicity after the first fraction. Treatment effects were assessed using a subjective scoring scale and feedback from patients and their families.